Entera Bio Stock

Entera Bio EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Entera Bio (ENTX) as of Aug 4, 2026 is -11.53 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -9.59 M USD — a change of 20.28% (lower).

EBITDA

-11.53 MUSD

YoY

20.28%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Entera Bio is 2026 -11.53 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Entera Bio was 2025 -9.59 M USD. It decreases by 20.28% lower compared to the previous year.
Access this data via the Eulerpool API

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Entera Bio is -11.53 M USD in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Entera Bio changed from -9.59 M USD to -11.53 M USD, representing a 20.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Entera Bio since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Entera Bio historically and in real time.

Access this data via the Eulerpool API

Income Statement — Entera Bio

All Key Metrics — Entera Bio